Document:

Exhibit 10.2

                           NATURAL HEALTH TRENDS CORP.
                               2050 Diplomat Drive
                                Dallas, TX 75234

                                              March 1, 2006

Robert H. Hesse
c/o Natural Health Trends Corp.
2050 Diplomat Drive
Dallas, TX  75234

Dear Bob:

          In connection with your continued employment as the Interim Chief
Executive Officer of Natural Health Trends Corp. (the "Company"), we are pleased
to offer you the following terms and conditions:

Title:              Interim Chief Executive Officer

Duties:             Duties and responsibilities customary for a chief executive
                    officer, including without limitation:

                    -- Develop a 2006 financial plan for the Company;

                    -- Manage the Company to achieve the financial plan;

                    -- Support the Company's Search Committee in its recruitment
                       of a permanent CEO;

                    -- Effect a seamless transition to a permanent CEO;

                    -- Develop a corporate culture for all employees and
                       distributors focused on implementing professional conduct
                       and best practices, particularly with respect to legal
                       and regulatory compliance;

                    -- Actively confer with the Company's Board of Directors
                       (the "Board") on all significant operational, financial
                       and strategic issues and be responsive to the Board's
                       reasonable requests and direction;

                    -- Assist the Board in resolving all matters relating to
                       former management and related issues; and
<PAGE>

                    -- Maintain positive relations with investors, market makers
                       and analysts, subject to compliance with applicable laws,
                       rules and regulations.

Term:               Term of engagement concludes when new CEO commences
                    employment - most likely by July 1, 2006

Base Pay:           $2,000 per day

Retention Bonus:    $300,000, $150,000 of which will be paid on the date hereof,
                    and $150,000 shall be paid within 5 days following the last
                    day of the Term, assuming your duties are discharged and
                    transition is effected to the reasonable satisfaction of the
                    Board

Benefits:           Travel and entertainment as available to senior executives
                    (in accordance with prior practice) and reasonable
                    reimbursement of rent for Dallas apartment during the Term

          We look forward to continuing to work together to make Natural Health
a success.

                                             NATURAL HEALTH TRENDS CORP.

                                             By /s/ SIR BRIAN WOLFSON
                                                --------------------------------
                                                Name:   Sir Brian Wolfson
                                                Title:  Chairman of the Board

Agreed to and Accepted:

/s/ ROBERT H. HESSE
--------------------------------
Robert H. Hesse

cc:  The Board of Directors
     Natural Health Trends Corp.

                                       2First Addendum to Roche Agreement

    EXHIBIT
      10.17

     

    cbmx

    COMBIMATRIX

    CORPORATION

    

    6500
      Harbour Heights Pkwy

    Muklteo,
      WA 98275

    

    Tel
      425.493.2000

    Fax
      425.493.2010

    

    www.combimatrix.com

    

    Via
      Overnight Courier

    25
      March
      2003

    Stefan
      Willemsen

    Roche
      Diagnostics GmbH

    Nonenwald
      2

    82377
      Penzberg

    Germany

    

    First
      Addendum to Roche/CBMX Research and Development Agreement

    

    Dear
      Stefan:

    As
      we
      discussed, we need to update Annex I in the current R&D Agreement to update
      the project milestones and priorities of the Committee and to add in completed
      milestones for the sake of completeness.

    

    Please
      sign both copies of this letter with a revised Annex I to substitute in the
      revised Annex I.

    

    Sincerely,

    Combimatrix
      Corporation

     

    /s/
Jeff
      Oster

     

    Jeff
      Oster

    Sr.
      Vice
      President for Intellectual Property

    

    Agreed
      to
      substitute revised Annex I

    Roche
      Diagnostics GmbH

     

    /s/
Stefan
      Willemsen

    Stefan
      Willemsen

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Annex
      I

    Development
      Program and Payment Schedule

    

    

    A  1
      K System

            

     

    
      	 Product	 Due
              Date	 Deliverable	
              Milestone Payment 

              In Mio US $

            
	
              *

               

            	
              *

            	
              *

               

            	
              *

               

               

               

               

            
	
              *

               

               

               

               

               

               

               

               

               

               

               

              *

               

               

               

               

               

               

               

               

            	
               

               

              *

               

               

              *

               

               

              *

               

               

               

              *

               

               

               

               

               

               

              *

               

               

               

               

            	
               

               

              *

               

               

              *

               

               

              *

               

               

               

              *

               

               

               

               

               

               

              *

            	
               

               

              *

               

               

               

               

               

              *

               

               

               

              *

               

               

               

               

               

               

               

              *

            

    

     

    *
      Omitted
      pursuant to a request for confidential treatment. The omitted material has
      been
      filed separately with the SEC.

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              *

               

               

               

               

            	
              *

               

               

               

               

               

               

              *

              
                 

              

            	
              *

               

               

               

               

               

               

              *

               

            	
               

              *

               

               

               

               

               

              *

            
	
              *

               

            	
               

               

               

              *

               

               

               

              *

               

               

               

              *

               

               

               

              *

               

               

               

               

               

            	
               

               

               

              *

               

               

               

              *

               

               

               

              *

               

               

               

              *

            	
               

               

               

              *

               

               

               

              *

               

               

               

               

               

               

               

              *

               

            
	
              *

               

            	
               

               

              *

            	
               

               

              *

               

            	 
	
               

              *

               

            	
               

               

               

              *

               

               

               

              *

               

            	
               

               

               

              *

               

               

               

              *

              *

               

            	
               

               

               

               

               

               

               

              *

              *

            

    

     

    
      *
        Omitted
        pursuant to a request for confidential treatment. The omitted material has
        been
        filed separately with the SEC.

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              *

            	
              *

            	
              *

               

               

            	
              *

               

            
	
              *

               

            	
              *

               

               

               

              *

            	
              *

               

               

               

              *

               

               

               

              *

               

            	
              *

               

               

               

              *

               

               

            

    

    

    

    B

    

    10
      K
      System and other development projects

    

    
      	
              *

               

            	
              *

            	
              *

               

            	
               

              *

               

               

            
	
              *

               

               

               

            	
              *

            	
              *

               

            	
               

              *

            
	
              *

               

               

               

            	
              *

            	
              *

               

            	 
	
              *

               

            	
              *

               

               

              *

            	
              *

               

               

              *

               

            	 

    

    

      *
        Omitted
        pursuant to a request for confidential treatment. The omitted material has
        been
        filed separately with the SEC.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]